Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis
Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.
You may also be interested in...
Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise.
Antibody targeting IL-23p19 yields clinical remission of ulcerative colitis after 12 weeks in the Phase III LUCENT-1 study. It also met all secondary endpoints, including reduction of bowel urgency.
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.